View Older Stories View More Recent Stories

Apr 14, 2022 07:02AM Cytosorbents (CTSO) to Expand Direct Sales of CytoSorb to the UK
Apr 14, 2022 07:00AM CytoSorbents To Expand Direct Sales of CytoSorb® to the United Kingdom, the Sixth Largest Medical Device Market in the World
Apr 7, 2022 07:00AM CytoSorbents Receives Approximately $740,000 from the New Jersey Business Tax Certificate Transfer Program
Apr 5, 2022 07:04AM Cytosorbents (CTSO) Appoints Jiny Kim, MBA to its Board of Directors
Apr 5, 2022 07:00AM CytoSorbents Appoints Jiny Kim, MBA to its Board of Directors
Mar 17, 2022 07:00AM CytoSorbents Highlights Activities at the Live 41st International Symposium on Intensive Care and Emergency Medicine (ISICEM)
Mar 8, 2022 04:15PM CytoSorbents Reports Fourth Quarter and Full Year 2021 Results and Provides 2022 Outlook
Feb 8, 2022 07:00AM CytoSorbents to Report Fourth Quarter and Full Year 2021 Operating and Financial Results
Feb 3, 2022 07:00AM CytoSorbents Announces Participation in Two Upcoming Virtual Investor Conferences
Feb 1, 2022 07:00AM First Patient Enrolled in the PROCYSS Multicenter Randomized Controlled Trial Evaluating CytoSorb® to Restore Hemodynamic Stability in Patients with Refractory Septic Shock
Jan 24, 2022 07:00AM New Publication Reports Significant Reductions in Perioperative Bleeding Complications Following Acute Aortic Dissection Surgery using CytoSorbents' Antithrombotic Drug Removal Technology
Jan 18, 2022 07:03AM Cytosorbents (CTSO) Reports Prelim Q4, Issues Stockholder Letter
Jan 18, 2022 07:00AM CytoSorbents Issues Stockholder Letter and Reports Preliminary Fourth Quarter and Full Year 2021 Revenue
Dec 21, 2021 07:05AM CytoSorbents Appoints Daniel Wendt, MD, PhD, MHBA, FECTS as Vice President, Medical Affairs Cardiovascular
Dec 20, 2021 07:12AM Cytosorbents (CTSO) Reports Publication of US CTC Multicenter Registry Results Using CytoSorb in Critically Ill COVID-19 Patients
Dec 20, 2021 07:10AM CytoSorbents Announces Publication of U.S. CTC Multicenter Registry Results Using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO)
Nov 15, 2021 04:30PM CytoSorbents to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum and Jefferies London Healthcare Conference
Nov 4, 2021 04:15PM CytoSorbents Reports Full Third Quarter 2021 Financial and Operational Results
Oct 20, 2021 07:06AM Cytosorbents (CTSO) Provides Comments on REMOVE Study Presentation
Oct 20, 2021 07:05AM CytoSorbents Comments on REMOVE Study Presentation
Oct 14, 2021 07:05AM First Patient Enrolled in U.S. STAR-T Pivotal Trial Evaluating the DrugSorb-ATR™ Antithrombotic Removal System to Remove Ticagrelor During Cardiothoracic Surgery
Oct 12, 2021 04:38PM Cytosorbents (CTSO) Receives Full FDA IDE Approval to Begin U.S. STAR-D Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR Antithrombotic Removal System During Urgent Cardiothoracic Surgery
Oct 12, 2021 04:38PM CytoSorbents Receives Full FDA Investigational Device Exemption (IDE) Approval to Begin U.S. STAR-D Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR™ Antithrombotic Removal System Durin
Oct 12, 2021 04:36PM Cytosorbents (CTSO) Prelim. Q3 Revenue Misses Consensus
Oct 12, 2021 04:35PM CytoSorbents Provides Preliminary Third Quarter Business Update and Revised 2021 Product Revenue Guidance
Oct 7, 2021 03:12PM Cytosorbents (CTSO) Announces Availability of Preliminary Data Abstracts from Two Endocarditis Studies, including the REMOVE study, to be Presented at the EACTS Conference
Oct 7, 2021 03:11PM CytoSorbents Announces Availability of Preliminary Data Abstracts from Two Endocarditis Studies, including the REMOVE study, to be Presented at the EACTS Conference
Sep 14, 2021 09:25AM CytoSorbents to Host International Webinar on the Worldwide Experience Using CytoSorb® in Critically Ill Patients with COVID-19
Sep 13, 2021 07:08AM CytoSorbents Commemorates World Sepsis Day and Sepsis Awareness Month with Key Sepsis-Related Events, Sponsorships and Studies
Sep 10, 2021 07:09AM Cytosorbents (CTSO) Announces Filing of IDE for U.S. Clinical Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR Antithrombotic Removal System During Urgent
Sep 10, 2021 07:08AM CytoSorbents Announces Filing of an Investigational Device Exemption (IDE) for the U.S. Clinical Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR™ Antithrombotic Removal System During U
Sep 8, 2021 04:15PM CytoSorbents Announces Webinar Discussing Topline Results from the U.S. CTC Registry using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO)
Sep 1, 2021 07:15AM Cytosorbents (CTSO) Topline Results from CytoSorbents' U.S. CTC Multicenter Registry Show High Survival using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECM
Sep 1, 2021 07:08AM Topline Results from CytoSorbents' U.S. CTC Multicenter Registry Demonstrate High Survival using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO)
Aug 30, 2021 07:18AM Cytosorbents (CTSO), Aferetica Launch PerSorb Adsorber and PerLife Organ Perfusion System in Italy
Aug 30, 2021 07:08AM CytoSorbents and Aferetica Announce the Commercial Launch in Italy of the PerSorb™ Adsorber and PerLife™ Organ Perfusion System, respectively, at the European Society of Organ Transplantation Cong
Aug 12, 2021 07:03AM Cytosorbents (CTSO) Announces Second U.S. FDA Breakthrough Device Designation Granted to DrugSorb-ATR Antithrombotic Removal System
Aug 12, 2021 07:03AM Second U.S. FDA Breakthrough Device Designation Granted to CytoSorbents' DrugSorb-ATR™ Antithrombotic Removal System Adding the Removal of Market-Leading Direct Oral Anticoagulants During Urgent Car
Aug 3, 2021 04:15PM CytoSorbents Reports Second Quarter 2021 Financial and Operational Results
Jul 30, 2021 07:08AM CytoSorbents Completes its Mission 100,000 International Fundraising Campaign to Fight the Spread of COVID-19 for Global Humanitarian Organization, CARE
Jul 19, 2021 07:08AM CytoSorbents to Report Second Quarter 2021 Operating and Financial Results
Jul 6, 2021 07:07AM Cytosorbents (CTSO) Receives Full FDA Approval of IDE for U.S. STAR-T Trial on Ticagrelor Removal During Cardiothoracic Surgery
Jul 6, 2021 07:05AM CytoSorbents Receives Full FDA Approval of Investigational Device Exemption (IDE) for U.S. STAR-T Trial on Ticagrelor Removal During Cardiothoracic Surgery
Jun 1, 2021 07:08AM CytoSorbents Appoints Terri Anne Powers, IRC as Vice President of Investor Relations and Corporate Communications
May 27, 2021 07:00AM CytoSorbents to Present at the Jefferies Virtual Healthcare Conference
May 25, 2021 07:08AM CytoSorb® Registered and Commercially Available in Singapore
May 19, 2021 07:00AM CytoSorbents to Present at the UBS Global Healthcare Virtual Conference and Oppenheimer MedTech, Tools and Diagnostic Summit
May 11, 2021 08:51AM Cytosorbents (CTSO) Secures $1.5M Sequential Phase II SBIR Contract to AdvanceTreatment of Severe Hyperkalemia in Traumatic Injury
May 11, 2021 08:50AM CytoSorbents Awarded $1.5 Million Sequential Phase II SBIR Contract to Advance the Treatment of Severe Hyperkalemia in Traumatic Injury
May 4, 2021 04:15PM CytoSorbents Reports First Quarter 2021 Financial and Operational Results
View More Recent Stories View Older Stories